Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewResearchpeer-review

  4. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX).

OBJECTIVE: The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption.

METHODS: Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP).

RESULTS: Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP).

CONCLUSION: Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.

Original languageEnglish
Article number116065
JournalBone
Volume152
Pages (from-to)1-7
Number of pages7
ISSN8756-3282
DOIs
Publication statusPublished - 1 Nov 2021

    Research areas

  • Bone turnover, CTX, Glucagon-like peptide-2 (GLP-2), Glucose-dependent insulinotropic polypeptide (GIP), Gut-bone axis, P1NP

ID: 66421156